Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAINED: Gazivaro vs Rituximab in DLBCL
NCT01659099Phase 3Terminated
- Sponsor
- LYSARC
- Start
- Sep 2012
- Primary completion
- Aug 2016
- Countries
- 2
01
Overview
A Phase 3 trial of obinutuzumab in diffuse large B-cell lymphoma (DLBCL), sponsored by LYSARC. Started Sep 2012; status: terminated.
02
Drugs
obinutuzumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01659099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01659099.